Submit an Investigational New Drug application for osanetant
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Sep 2021
- Delivered
- Q4 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Q3 2021: IND submission for osanetant is anticipated in the third quarter of 2021”
What we found
Evidence strength A What the grades mean
A later 10-Q said the IND was intended for Q4 2021, and a subsequent 10-Q says it was submitted in Q4 2021, after the Q3 2021 deadline.
-
A Acer Therapeutics Inc. 10-Q filed 2021-11-19
“In the fourth quarter of 2021, we intend to submit a protocol for the prospective study, along with an investigational new drug application” ✓ confirmed on the page
-
A Acer Therapeutics Inc. 10-K filed 2022-03-02
“Announced in December 2021 FDA clearance of our Investigational New Drug (“IND”) application for our selective non-peptide neurokinin 3 receptor (“NK3R”) antagonist, ACER-801 (osanetant)” ✓ confirmed on the page
-
A Acer Therapeutics Inc. 10-Q filed 2022-05-16
“In the fourth quarter of 2021, we submitted a protocol for the prospective pivotal trial, along with an IND.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- Osanetant IND submission
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Acer Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C069308-024922 · Corrections policy